Perilla extract shown to inhibit allergic response "Allergies are now the most prevalent and rapidly increasing chronic health problem in industrialized countries," according to researchers. Because industrial advances have brought about increased chemical pollution in our environment, patients suffering from chronic allergic diseases are more heavily affected. Chronic allergic diseases include bronchial asthma and atopic dermatitis. Bronchial asthma is characterized by recurring symptoms of wheezing, shortness of breath, chest tightness, and coughing. Atopic dermatitis, commonly known as eczema, is characterized by recurring scaly and itchy rashes. Individuals with these conditions may have a family history of allergies such as hay fever or eczema. Treatment of allergy symptoms often involves the use of prescription or over-the-counter antihistamine or decongestant medications. Unfortunately, these medications may cause unwanted side effects such as hyperactivity or drowsiness, increased blood pressure, or dryness of the mouth, nose, and throat. In search of an alternative treatment, researchers conducted a study to evaluate the antiallergic effects of perilla extract (Perilla frutescens)—an herb prescribed for respiratory conditions in Traditional Chinese Medicine (TCM) and Kampo (traditional Japanese herbal medicine). Mice were orally administered perilla extract or tranilast (an antiallergic drug) at a dose of 500 mg per kg of body weight. After 30 minutes, they were injected with a substance to induce a severe allergic reaction in the skin or saline to produce no effect. Subsequently, the effects of perilla extract and tranilast were compared and calculated. Results demonstrated a 43% inhibition of allergic reaction by perilla extract. This data led Makino and colleagues to conclude in Biological & Pharmaceutical Bulletin that "...oral treatment [with] perilla [extract] suppresses allergic reaction." SOURCE: Biol Pharm Bull 2001;24(10):1206-09. Advanced Nutrition Publications ©2002
More Articles:
Chronic stuffy nose tied to high blood pressure Copyright 1998-2001, Reuters Limited. Reuters content is the intellectual property of Reuters Limited. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. Reuters, the Reuters Dotted Logo and the Sphere Logo are registered trademarks of the Reuters group of companies around the world. | |||||
Printable version of the article 